Literature DB >> 27041528

MUM-1 and bcl-2 Positive Primary Diffuse Large B Cell Non-Hodgkin's Lymphoma of the Colon.

Vladimir Jurisić1, Mirjana Plećić2, Natasa Colović3, Vesna Čemerikić-Martinović4, Marko Janković3, Milica Čolović3.   

Abstract

Primary diffuse large B cell lymphoma (DLBCL) presents as a nodal and extranodal disease. The most common extranodal site is the gastrointestinal tract (GI), with the stomach most frequently involved, followed by the small bowel. Primary DLBCL of the large bowel accounts for 0.2%-1.2% of all colonic tumors. We present two patients who underwent radical resections of right colonic tumors. They were diagnosed with primary colonic DLBCL following histological and immunohistochemical testing of the excised tissues, and were determined as being in stage IIE of the disease. The tumors expressed CD20 markers. Both received multi-agent chemotherapy with combined immunotherapy and remain in complete remission at 4 and 5 years.

Entities:  

Mesh:

Year:  2016        PMID: 27041528     DOI: 0161904/AIM.0014

Source DB:  PubMed          Journal:  Arch Iran Med        ISSN: 1029-2977            Impact factor:   1.354


  1 in total

1.  Comparative randomized trial evaluating the effect of proton pump inhibitor versus histamine 2 receptor antagonist as an adjuvant therapy in diffuse large B-cell lymphoma.

Authors:  Sahar K Hegazy; Sahar M El-Haggar; Suzan A Alhassanin; Eman I El-Berri
Journal:  Med Oncol       Date:  2021-01-04       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.